Novogen says Cantrixil trial progressing as planned
08 August, 2017Novogen, an ASX-listed oncology drug development company, has announced that its phase I clinical trial of Cantrixil in ovarian cancer is progressing as planned.
VivaGel BV trials declared a success
08 August, 2017Starpharma has announced that its two phase 3 trials of VivaGel BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective, demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.
Nanocapsules could create artificial organs, treat incurable diseases
27 July, 2017 by Adam FloranceResearchers have developed a significant advancement in manufacturing better-quality nanocapsules which may lead the way to new treatments for currently incurable diseases, including diabetes.
Aus start-up completes first-in-human trial of bone 'glue'
21 July, 2017Australian biotech company Trimph has successfully completed a first-in-human trial of its proprietary bone 'glue' — said to be the only bone graft substitute in the world to be applied in liquid form.
Stem cells show potential for asthma treatment
06 July, 2017Monash University scientists have published the results of their study into mesenchymal stem cells (MSCs) from Cynata Therapeutics, revealing that the company's technology holds promise as a treatment for chronic asthma.
Innate reveals "distressing" MS trial results
30 June, 2017Innate Immunotherapeutics has reluctantly announced that its MS therapy MIS416 showed no meaningful or statistically significant results in a recent Phase 2B trial, with the company's shares dropping a whopping 92% as a result.
Prima says IMP321 trial progressing well
29 June, 2017Prima BioMed has announced that the company's two active clinical trials in IMP321 are progressing well.
Canadian CRO selected to reformulate cancer inhibitor
27 June, 2017PharmAust has appointed contract research organisation BRI Pharmaceutical Research Inc to reformulate its lead drug candidate, Monepantel (MPL), for clinical trials.
Clinical trials provide $1.1bn to economy
22 June, 2017Clinical trials accounted for roughly $1.1 billion in gross expenditure in 2015, and the annual expenditure could reach 2 billion in the next 10 years.
The week in medical cannabis: ethics approval granted, new JV formed
20 June, 2017It's been a big week for Australia's growing medical cannabis industry, with ethics approval granted for two human trials as well as the formation of a new joint venture.
Chr. Hansen expands strain library
16 June, 2017Global bioscience company Chr. Hansen has expanded its strain library of potential microbiome modulating strains.
Building brains with bioengineering
09 June, 2017Using a combination of bioengineering and stem cell culture, scientists have formed brain-like structures called organoids that resemble the shape of a human embryo.
Positive burns trial results and a new CEO at Avita Medical
05 June, 2017Avita Medical has announcement the appointment of Dr Michael Perry as its new CEO, as well as the results of a US pivotal burns trial.
Patenting biotech in Australia — an update
02 June, 2017 by Malcolm Lyons, Patent AttorneyObtaining a patent for a biotech invention is crucial to its further development and eventual commercialisation. Whether it's a new drug, insecticide or diagnostic, the developer needs to know they will have exclusive ownership of the invention and enjoy a return on their usually significant investment when they take the invention to the market.
Nominations open for AusBiotech and Johnson & Johnson Industry Excellence Awards
31 May, 2017Nominations have opened for the AusBiotech and Johnson & Johnson Industry Excellence Awards, to be presented at AusBiotech 2017 on 25 October.
